source
- Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.Fierce Biotech · 15h ago↗ source
- Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidanceLabcorp continues to power along as it posts strong quarterly earnings led by growth in its diagnostics and lab services and triggering the medtech to raise its full-year guidance.Fierce Biotech · 16h ago↗ source
- Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to oneTakeda has dropped another celiac disease therapy from its phase 2 pipeline, leaving the company with just one shot at treating the condition.